Flight evaluation of the effect of winglets on performance and handling qualities of a single-engine general aviation airplane

A flight evaluation was conducted to determine the effects of winglets on the performance and handling qualities of a light, single-engine general aviation airplane. The performance measurements were made with a pace airplane to provide calibrated airspeeds; uncalibrated panel instruments in the test airplane were used to provide additional quantitative performance data. These tests were conducted with winglets on and off during the same day to measure relative performance effects. Handling qualities were evaluated by means of pilot comments. Winglets increased cruise speed 8 knots (5.6 percent) at 3962 m (13,000 ft) density altitude and 51 percent maximum continuous power setting. Maximum speed at 3962 m was virtually unchanged. Rate of climb increased approximately 6 percent, or 0.25 m/sec (50 ft/min), at 1524 m (5000 ft). Stall speed was virtually unchanged. Handling qualities were favorably affected

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

Targeted cancer therapy requires the rapid and accurate identification of genetic abnormalities predictive of therapeutic response. We sought to develop a high-throughput genotyping platform that would allow prospective patient selection to the best available therapies, and that could readily and inexpensively be adopted by most clinical laboratories. We developed a highly sensitive multiplexed clinical assay that performs very well with nucleic acid derived from formalin fixation and paraffin embedding (FFPE) tissue, and tests for 120 previously described mutations in 13 cancer genes. Genetic profiling of 250 primary tumours was consistent with the documented oncogene mutational spectrum and identified rare events in some cancer types. The assay is currently being used for clinical testing of tumour samples and contributing to cancer patient management. This work therefore establishes a platform for real-time targeted genotyping that can be widely adopted. We expect that efforts like this one will play an increasingly important role in cancer management

Parental origin of sequence variants associated with complex diseases

To access publisher full text version of this article. Please click on the hyperlink in Additional Links fieldEffects of susceptibility variants may depend on from which parent they are inherited. Although many associations between sequence variants and human traits have been discovered through genome-wide associations, the impact of parental origin has largely been ignored. Here we show that for 38,167 Icelanders genotyped using single nucleotide polymorphism (SNP) chips, the parental origin of most alleles can be determined. For this we used a combination of genealogy and long-range phasing. We then focused on SNPs that associate with diseases and are within 500 kilobases of known imprinted genes. Seven independent SNP associations were examined. Five-one with breast cancer, one with basal-cell carcinoma and three with type 2 diabetes-have parental-origin-specific associations. These variants are located in two genomic regions, 11p15 and 7q32, each harbouring a cluster of imprinted genes. Furthermore, we observed a novel association between the SNP rs2334499 at 11p15 and type 2 diabetes. Here the allele that confers risk when paternally inherited is protective when maternally transmitted. We identified a differentially methylated CTCF-binding site at 11p15 and demonstrated correlation of rs2334499 with decreased methylation of that site.info:eu-repo/grantAgreement/EC/FP7/21807

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Qualitative and Quantitative-determination of Thermal-degradation Products of Type-c Hydraulic Fluids

A qualitative and quantitative analysis of the thermal decomposition mixtures of some type C hydraulic fluids has been done. The decomposition products were identified by gas chromatography/mass spectrometry. Due to the nature of some decomposition compounds, a specific pre-column derivatization technique in combination with a well-adapted capillary column was necessary. Type C hydraulic fluids only slightly decompose in the temperature range from 500 to 700-degrees-C, resulting in low levels of decomposition compounds present in the inhalation chamber in which laboratory animals are placed. The quantitative composition supports earlier research on the acute inhalation toxicity testing on laboratory animals

Illicit Drug Trends Globally

© 2017 Elsevier Inc. All rights reserved. Human consumption of psychoactive substances goes back to prehistory and has always been a global phenomenon even if patterns of use and prevalence rates vary considerably by time and place. The concept of problematic drug use, and concerns about how this should be defined and measured, is, however, a more recent development and until recently mostly associated with a restricted number of Western industrialized countries. This has changed and with increasing globalization drug problems are now both more relevant to, and more recognized in, low- and middle-income countries. Demographic factors also mean that the most significant public health implications of substance misuse are already probably impacting most on the developing rather than the developed world. This article reviews the methodological approaches that are commonly used to monitor the normally hidden behavior of drug use and associated risks and reviews the global and regional structures that exist for undertaking this task. An overview is also provided for the main types of illicit drugs and their places on the global scene, with links to data sources to allow the reader access to more up-to-date information as it becomes available